Hwail Pharm Co., Ltd. (061250) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hwail Pharm Co., Ltd. (061250:KRX), powered by AI.

Current Price
₩8,210
P/E Ratio
-281.4
Market Cap
65.6B
Sector
Healthcare
What is the Hwail Pharm Co., Ltd. stock price forecast?

Hwail Pharm Co., Ltd. is currently trading at ₩8,210. View real-time AI analysis on Alpha Lenz.

What is Hwail Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Hwail Pharm Co., Ltd. on Alpha Lenz.

What is Hwail Pharm Co., Ltd.'s P/E ratio?

Hwail Pharm Co., Ltd.'s P/E ratio is -281.4.

Hwail Pharm Co., Ltd.

KRX · 061250
₩8,210+420(+5.39%)Market closedKRX regular session 09:00–15:30 KST
Ask about Hwail Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Hwail Pharm Co., Ltd. trades at a P/E of -281.4 (undervalued) with modest ROE of -0.1%.

Ask for details

Company Overview

Hwail Pharm Co., Ltd. is a distinguished company in the pharmaceutical sector that specializes in the research, development, and production of various pharmaceutical products. With a robust focus on innovation, it fosters advancements in medical treatments and health solutions. The company's product portfolio typically includes a range of medicinal drugs, catering to ailments across different therapeutic areas. Hwail Pharm Co., Ltd. plays a critical role in the healthcare industry by contributing to the enhancement of public health through its pharmaceutical offerings. Known for adhering to high-quality standards, it ensures that its products comply with stringent regulatory requirements, thus maintaining trust among healthcare professionals and patients alike. Its impact is felt across hospitals, pharmacies, and clinics, where its products are used to improve patient care and outcomes. As part of its market presence, Hwail Pharm Co., Ltd. is committed to the continuous development of its product lines and exploring new treatment avenues, thereby holding a significant place in the pharmaceutical market.

CEO조경숙, 서생규(각자대표)
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩65,572,979,360Market Cap
₩100,817,433,490Revenue
8.42MShares Out
0Employees

Margins

6.59%Gross
0.62%EBITDA
-2.25%Operating
-0.34%Pre-Tax
-0.23%Net

Valuation

-281.41P/E
0.32P/B
0.65EV/Sales
7.12EV/EBITDA
8.32P/FCF

Growth (CAGR)

-8.60%Rev 3Yr
-3.99%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-0.11%ROA
-0.11%ROE
-0.06%ROIC

Financial Health

₩61,468,769,160Cash & Cash Equivalents
₩-55,180,160,760Net Debt
3.04%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Hwail Pharm Co., Ltd. (ticker: 061250) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $65.6B.

The current price is ₩8,210 with a P/E ratio of -281.41x and P/B of 0.32x.

ROE is -0.11% and operating margin is -2.25%. Annual revenue is $100.8B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Hwail Pharm Co., Ltd. (061250) Stock Forecast 2026 ₩8,210 — Price, Financials & Analyst Targets | Alpha Lenz